secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sionna Therapeutics, Inc. (SION)
CIK:        0002036042
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001628280-26-012993
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sionna Therapeutics Q4 2025 net loss $20.4M; cash $310.3M funds into 2028
-------------------------------------------------------------------------

- Net loss $20.4M (Q4) and $75.3M (FY 2025) vs $15.8M and $61.7M in 2024.
- Cash and equivalents $310.3M as of Dec 31, 2025; expected to fund operations into 2028.
- Phase 2a PreciSION CF trial of SION-719 on track; topline data expected mid-2026.
- Phase 1 dual combo trial of SION-451 with SION-2222/SION-109 on track; data mid-2026.
- R&D expenses $15.2M (Q4) and $60.3M (FY); G&A expenses $8.4M (Q4) and $28.7M (FY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2036042/000162828026012993/0001628280-26-012993-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2036042/000162828026012993/sion-20260302.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-012993

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer